Elevated PSA at Midlife Predicts Aggressive Prostate Cancer in Blacks
A midlife PSA value above the 90th percentile was associated with greater risk of total and aggressive prostate cancer in black men.
Prostate And Other Male Cancers
Annual PSA Screening Best for Reducing Prostate Cancer Deaths
A study of 400,887 men in an integrated health system, the first to evaluate various PSA screening intervals and age groups, concluded that yearly screening is the interval of choice.
Prostate Cancer Brachytherapy Outcomes Linked to PSADT
Shorter PSA double times are associated with worse disease-specific, metastasis-free, and overall survival, study finds.
PSA Level 3 Months After Radiation Tx May Predict Outcome
Findings for men with intermediate- and high-risk prostate cancer.
Novel Blood Test Improves Detection of High-Grade Prostate Cancer
IsoPSA can correctly rule out high-grade prostate cancer 93% of the time and thus has the potential to reduce the number of unnecessary prostate biopsies.
Optimal Post-Radical Prostatectomy Follow-up Schedule Proposed
Investigators suggest PSA testing frequencies based on post-operative baseline PSA.
Gleason 4+3 vs 3+4 PCa Tied To Higher Risk of Metastasis at Diagnosis
Men with Gleason score (GS) 4+3 prostate cancer have a 3-fold higher risk of distant metastasis at diagnosis than those with GS 3+4 PCa.
Single PSA Screening Has No Effect on Prostate Cancer Mortality
Findings from a large study of men in the United Kingdom do not support single PSA testing for population-based screening.
State Variation in PSA Screening After the 2011-2012 USPSTF Update
Not only is there immense state-by-state heterogeneity in PSA screening, but there is also marked variation within each state.
Early Prostate Cancer Salvage ADT Therapy Better
Among men who had PSA failure following radiation therapy for localized PCa, those with a long PSA doubling time had an increased risk of PCa mortality if they started androgen-deprivation therapy later.
- Loading...
Loading...
Next post in Genitourinary Cancers Symposium
Loading... 
Loading...